BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yotebieng M, Edmonds A, Lelo P, Wenzi LK, Ndjibu PT, Lusiama J, Kabuayi JP, Behets F. High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo. AIDS 2015;29:2055-7. [PMID: 26352882 DOI: 10.1097/QAD.0000000000000791] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Kebede F, Kebede B, Kebede T, Agmasu M. Effect of Isoniazid Preventive Therapy on the Incidence of Tuberculosis among Seropositive Children Attending HIV/AIDS Care in Two General Hospitals, Northwest Ethiopia, 2021. J Trop Med 2021;2021:9996953. [PMID: 34545289 DOI: 10.1155/2021/9996953] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Robert M, Todd J, Ngowi BJ, Msuya SE, Ramadhani A, Sambu V, Jerry I, Mujuni MR, Mahande MJ, Ngocho JS, Maokola W. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study. BMC Infect Dis 2020;20:276. [PMID: 32276618 DOI: 10.1186/s12879-020-04997-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis 2017;21:537-43. [PMID: 28399969 DOI: 10.5588/ijtld.16.0775] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Sensalire S, Karungi Karamagi Nkolo E, Nabwire J, Lawino A, Kiragga D, Muhire M, Kadama H, Katureebe C, Namuwenge P, Musinguzi J, Calnan J, Seyoum D. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda. AIDS Res Ther 2020;17:28. [PMID: 32460788 DOI: 10.1186/s12981-020-00285-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Tram KH, Mwangwa F, Atukunda M, Owaraganise A, Ayieko J, Plenty A, Kwariisima D, Clark TD, Petersen ML, Charlebois ED, Kamya MR, Chamie G, Havlir DV, Marquez C; SEARCH Collaboration. Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care. J Acquir Immune Defic Syndr 2017;76:e115-7. [PMID: 28885271 DOI: 10.1097/QAI.0000000000001540] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lwevola P, Izudi J, Kimuli D, Komuhangi A, Okoboi S. Low level of tuberculosis preventive therapy incompletion among people living with Human Immunodeficiency Virus in eastern Uganda: A retrospective data review. J Clin Tuberc Other Mycobact Dis 2021;25:100269. [PMID: 34504952 DOI: 10.1016/j.jctube.2021.100269] [Reference Citation Analysis]
7 Kay AW, Thivalapill N, Skinner D, Dube GS, Dlamini N, Mzileni B, Fuentes P, Ustero P, Adams LV, Mandalakas AM. Predictors of suboptimal adherence to isoniazid preventive therapy among adolescents and children living with HIV. PLoS One 2020;15:e0243713. [PMID: 33332462 DOI: 10.1371/journal.pone.0243713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]